Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SCH 900636 · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| Org 34517 | EXPERIMENTAL | Org 34517 titrated to 900 mg daily for 2 weeks |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| SCH 900636 | DRUG | Org 34517 300 mg on Day 1, 600 mg on Day 2, then 900 mg daily starting from Day 3. Subjects in this arm were also to continue the "usual treatment" for psychotic major depression. |
| Placebo | DRUG | Placebo |
Inclusion Criteria: * have attended Screening, Baseline, Visit Day 15, Day 29 and Day 43 of previous trial 28130; * have a CGI of Severity score of 3 or greater at Day 43 of previous trial 28130 and at Day 1 of current trial 28133, or a lower score when the investigator is of the opinion that furth...
SCH 900636 is an investigational small molecule being studied for the treatment of depressive disorders, including psychotic disorders and depression. It is in Phase 2 clinical development and has not been approved by regulatory authorities.
SCH 900636 is being developed by Merck & Company, Inc., which is publicly traded under the ticker symbol MRK. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug.
SCH 900636 is in Phase 2 clinical development. It is an investigational drug, meaning it has not yet been approved for commercial use. One Phase 2 trial has been completed, and the drug is no longer in active clinical trials.
SCH 900636 has been studied in one completed Phase 2 clinical trial, identified as NCT00844922. This trial evaluated the safety of SCH 900636 in patients who had previously received the drug in an earlier study, enrolling 16 participants.
SCH 900636 is also known as Org 34517. The completed clinical trial NCT00844922 references Org 34517 in its title, indicating that these names refer to the same investigational drug being developed by Merck.